oncbrain — oncology meeting digest

PBS Proton vs IMRT Capsular Contracture Post-Mastectomy

Wed, 20 May 2026 00:00:00 GMT

[Unclear] PBS proton vs IMRT in post-mastectomy reconstruction: capsular contracture risk comparison; no effect size reported in source. Eligible: Post-mastectomy pts undergoing implant reconstruction, PMRT candidates

LS-SCLC 54 Gy SIB vs 45 Gy (NCT03214003)

Wed, 20 May 2026 00:00:00 GMT

[Challenges SOC] 54 Gy SIB vs 45 Gy in LS-SCLC: mOS 60.7 vs 39.5mo, HR 0.55 (0.37-0.72), p=0.003, no toxicity increase. Eligible: LS-SCLC, untreated or 1 prior chemo cycle, ECOG 0-1, age 18-70

Bladder-preserving TMT for MIBC — prognostic factors for recurrence and survival (ESTRO 2026)

Tue, 19 May 2026 00:00:00 GMT

[Confirmatory] Multicenter Spanish TMT cohort (n=369 MIBC): CLR 63.7%; 5-FU-based CRT and image-guided RT predict response. Eligible: MIBC cT2-T4aN0M0, median age 76, selected for bladder preservation, TMT-eligible

Single-fraction SABR for primary NSCLC and lung oligometastases (pooled, n=1687)

Tue, 19 May 2026 00:00:00 GMT

[Early signal] SF-SABR pooled analysis (n=1687): LC 90-93% at 2yr, G3+ AEs 2.9%, mOS 3.5yr (primary NSCLC) and >4yr (oligomets). Eligible: Primary NSCLC (early-stage, SABR candidate) or pulmonary oligomets, multi-instit

ePLND vs PSMA PET staging for prostate cancer (AUA 2026)

Tue, 19 May 2026 00:00:00 GMT

[Challenges SOC] AUA 2026 review: PSMA PET NPV ~96% may safely guide ePLND omission in intermediate-risk prostate; ePLND therapeutic benefit unproven in RCTs. Eligible: Newly diagnosed intermediate-to-high-risk prostate cancer, RP planned

OPERA Trial (5-year rectal preservation)

Mon, 18 May 2026 00:00:00 GMT

[Caveats dominate] OPERA post-hoc: W14 DRE+rectoscopy reliably identifies cCR; 5-yr organ preservation 75% vs 83% (Arm A vs B, p=0.24). Eligible: Locally advanced rectal cancer, post-NAT, organ preservation candidate

INRT-AIR & DARTBOARD (ENI omission in HNSCC)

Mon, 18 May 2026 00:00:00 GMT

[Early signal] ENI omission via INRT in HNSCC: 5-yr elective nodal recurrence 0%, 5-yr OS 87%, 5-yr PFS 74% across 117 pts. Eligible: HNSCC oropharynx/larynx/hypopharynx, stage I-IVB (excl. T1-2N0 larynx), treated

TORPEdO (CRUK/18/010)

Mon, 18 May 2026 00:00:00 GMT

[Challenges SOC] TORPEdO: IMPT vs IMRT in OPSCC, no difference in patient-reported UW-QoL composite at 12 months; phase 3 RCT, N=205. Eligible: Oropharyngeal SCC requiring bilateral neck concurrent CRT, p16+/-

NRG/RTOG 1005

Mon, 18 May 2026 00:00:00 GMT

[Practice-changing] Concurrent boost during WBI noninferior to sequential boost for IBR (HR 1.31, 90% CI 0.84-2.04) with no toxicity or cosmesis penalty; saves treatment time. Eligible: High-risk early breast cancer, post-lumpectomy, BCT candidates

HCC EBRT multinational IPD cohort

Mon, 18 May 2026 00:00:00 GMT

[Confirmatory] HCC EBRT multinational IPD (n=4,913): mOS 4.6yr BCLC-A, comparable to resection/ablation. Eligible: HCC BCLC-0/A, treatment-naive and experienced, eligible for ablative EBRT

EXTEND Trial

Mon, 18 May 2026 00:00:00 GMT

[Early signal] EXTEND phase II: MDT+SOC improves PFS vs SOC across oligometastatic histologies, HR 0.54 (0.41-0.72), p<0.001, 53-mo follow-up. Eligible: Oligometastatic solid tumors, 1-5 mets, multiple histologies, on SOC systemic th

FASTRACK II (TROG 15.03)

Mon, 18 May 2026 00:00:00 GMT

[Early signal] FASTRACK II: 100% local control at 36, 60, and 84 months with SABR for primary RCC (N=70, median f/u 62 mo). Eligible: Inoperable or surgery-declined primary RCC, ≤10 cm, N0-N1, median age 77

PEACE 2

Mon, 18 May 2026 00:00:00 GMT

[Challenges SOC] PEACE 2: pelvic RT did not improve cPFS vs prostate-only RT in VHR prostate (HR 0.81, p=0.088); no effect on MFS, OS, or PCSS. Eligible: VHR localized prostate (Gleason ≥8/T3-4/PSA ≥20), N0M0 conventional imaging

HEAT Trial

Mon, 18 May 2026 00:00:00 GMT

[Early signal] HEAT: AHRT non-inferior to EHRT for BF at 4.25y interim (7% vs 7.4%, P non-inf = 0.007) in low-intermediate risk PCa. Eligible: Low-intermediate risk localized PCa, IPSS <12

PACE-NODES

Sun, 17 May 2026 00:00:00 GMT

[Early signal] PACE-NODES: pelvic nodal SBRT adds short-term GI toxicity (28% vs 21% G≥2) vs prostate-only SBRT; cancer control endpoint not yet mature. Eligible: High-risk localised prostate (T3a-T4 or Gleason 8-10 or PSA >20 ng/ml), 12-36mo

RADIOSA

Sun, 17 May 2026 00:00:00 GMT

[Caveats dominate] RADIOSA post-hoc: median MFS 16.6mo vs NR, HR 0.39 favoring SBRT+ADT in oligorecurrent prostate cancer. Eligible: Oligorecurrent prostate cancer, SBRT-eligible at recurrence

PIVOTALboost

Sun, 17 May 2026 00:00:00 GMT

[Confirmatory] PIVOTALboost phase 3: focal boost + pelvic node RT (20 fractions) safe at 2 years; G2+ late bowel/bladder similar across all arms. Eligible: High-risk localised prostate cancer, 20-fraction IMRT candidates

PRIME

Sun, 17 May 2026 00:00:00 GMT

[Early signal] PRIME interim: 5-fraction SBRT + whole-pelvis RT comparable to moderate hypofractionation at 1-2yr; primary BFFS endpoint immature, 4-5yr data awaited. Eligible: High-risk/node-positive non-metastatic PCa, ECOG 0-2, ADT-eligible

PEACE-2

Sun, 17 May 2026 00:00:00 GMT

[Challenges SOC] PEACE-2: pelvic RT did not improve cPFS vs prostate-only RT (HR 0.81, p=0.088) in VHR prostate cancer with 3yr ADT. Eligible: Very high-risk localized prostate (≥2: GS ≥8, T3-T4, PSA ≥20), N0M0, 3yr ADT

Dutch Breast Boost Analysis

Sun, 17 May 2026 00:00:00 GMT

[Caveats dominate] Dutch DBRT registry: 10yr IBTR 1.2% (boost vs no boost) for 0-2 RF pts post-BCS, supporting omission in modern systemic therapy era. Eligible: Early breast cancer, post-BCS whole-breast RT, modern systemic therapy era

HypoG-01

Sun, 17 May 2026 00:00:00 GMT

[Confirmatory] HypoG-01 secondary analysis: patterns of failure comparable between 40 Gy/15 fx and 50 Gy/25 fx; LRR infrequent, most events were distant recurrence or second malignancy. Eligible: Early breast cancer, post-op adjuvant RT, hypofractionation eligible

DBCG HYPO

Sun, 17 May 2026 00:00:00 GMT

[Confirmatory] DBCG HYPO 10-yr: 40Gy/15fr reduced grade 2-3 induration vs 50Gy/25fr (19.5% vs 24.7%, HR 0.76, p=0.005) with no difference in recurrence or survival. Eligible: Early node-negative breast cancer or DCIS, adjuvant whole-breast RT indication

APBI-IMRT Florence

Sun, 17 May 2026 00:00:00 GMT

[Confirmatory] APBI-IMRT Florence: 15-yr IBTR 7.7% vs 4.2% (HR 1.57, p=0.17), no difference in locoregional control, DM, or OS. Eligible: Early breast cancer post-BCS, pT <25 mm, FSM ≥5 mm, age >40 yrs

RAPCHEM

Sun, 17 May 2026 00:00:00 GMT

[Early signal] RAPCHEM 10-yr: response-adapted locoregional RT de-escalation post-NAC yields <3% recurrence in breast. Eligible: Clinically node-positive breast, achieving nodal pCR after neoadjuvant chemother

IMPORT HIGH

Sun, 17 May 2026 00:00:00 GMT

[Confirmatory] IMPORT HIGH 10yr: 48Gy SIB IBTR 3.7% vs sequential 3.5%; 53Gy higher at 5.5%; SIB confirmed as SOC. Eligible: Early breast cancer (pT1-3, pN0-pN3a, M0), post-BCS requiring tumour bed boost R

DBCG RT Natural

Sun, 17 May 2026 00:00:00 GMT

[Early signal] DBCG RT Natural: PBI 40Gy/15fr cut 4-yr LR to 1.5% vs 9.8% without RT in older ER+ pT1N0 breast cancer. Eligible: Age ≥60, pT1N0, ER+, HER2-normal, grade 1-2, BCT, margin ≥2mm

EORTC IM-MS (22922/10925)

Sun, 17 May 2026 00:00:00 GMT

[Challenges SOC] EORTC IM-MS 20y: OS null (HR 1.00) despite BCM improvement (HR 0.82), offset by late non-BCM excess (HR 1.26). Eligible: Stage I-III breast cancer, adjuvant RT

OLIGOMA

Sun, 17 May 2026 00:00:00 GMT

[Early signal] OLIGOMA: mPFS 35.8 vs 20.4mo (HR 0.48, p=0.021) with MDT + systemic vs systemic alone in oligometastatic breast cancer. Eligible: Oligometastatic breast cancer, ≤5 mets, any treatment line, predominantly ER+ HE

EXTEND

Sun, 17 May 2026 00:00:00 GMT

[Early signal] EXTEND phase II RCT, MDT+SOC vs SOC in oligometastatic solid tumors: primary all-basket analysis published JCO May 2026.

OLIGOCARE

Sun, 17 May 2026 00:00:00 GMT

[Early signal] OLIGOCARE registry: SBRT for OMD, 88.6% LC at 3yr (n=2447); CRC highest local failure at 19.6%. Eligible: Oligometastatic solid tumors, 1-5 lesions, SBRT-eligible, mixed histologies